Zeo ScientifiX, Inc. (ZEOX) stock
Close on Oct 19, 2026Market cap $7.08MP/E –Yield –
Zeo ScientifiX, Inc. reported revenue of $6.99M for the twelve months to Apr 30, 2026. Free cash flow was -$741.00K. At the latest close the market valued the company at $7.08M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Apr 30, 2026
Valuation
- Market cap
- $7.08M
- P/E ratio
- –
- Price to sales
- 1.01
- Price to book
- 9.94
- Dividend yield
- –
- Free cash flow yield
- -10.47%
Fundamentals
- Revenue
- $6.99M
- Net income
- -$3.88M
- EPS, diluted
- -$0.58
- Free cash flow
- -$741.00K
- Book value per share
- $0.09
- Diluted shares
- 8M
Trading
- Previous close
- $0.91
- Open
- $0.95
- Day's range
- $0.91 – $0.95
- Volume
- 2,400
- Average volume (20 days)
- 6,750
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZEOX | S&P 500 | Difference | ZEOX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.9% | +0.6% | −34.5 pts | ||
| 3 months | -49.9% | +3.4% | −53.2 pts | ||
| Year to date | -66.3% | +13.3% | −79.6 pts | ||
| 1 year | -54.4% | +16.6% | −71.0 pts | ||
| 3 years | -49.3% | +86.4% | −135.7 pts | -20.3% | +23.1% |
| 5 years | -92.8% | +81.9% | −174.6 pts | -40.8% | +12.7% |
| 10 years | -93.5% | +318.9% | −412.3 pts | -23.9% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zeo ScientifiX filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- ZEO ScientifiX Reports Strong Revenue Growth Of For Three Months and Six Months Ended April 30, 2026Results
About Zeo ScientifiX
Biological Products, (No Diagnostic Substances)
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical firm that develops and manufactures biological therapies for regenerative medicine, degenerative conditions, and topical aesthetic uses. The company creates proprietary therapeutics from ethically sourced birth tissues, such as amniotic fluid and Wharton's jelly, as well as autologous patient blood. Its primary offerings include Zofin, an amniotic fluid-derived biologic containing extracellular vesicles and nanoparticles, and Patient Pure X, a blood-derived autologous treatment for pain and musculoskeletal conditions. The company also supplies topical aesthetic formulations. It distributes these biologics and associated services primarily to healthcare providers, including physicians, clinics, and medical practices that administer cellular treatments to patients.
Company profile, executives and historyZeo ScientifiX stock: common questions
What is Zeo ScientifiX's stock price?
ZEOX closed at $0.91 on Oct 19, 2026, up 0.15% on the day.
What is Zeo ScientifiX's market cap?
Zeo ScientifiX was worth $7.08M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ZEOX's P/E ratio?
Zeo ScientifiX lost money over the twelve months to Apr 30, 2026 (diluted EPS -$0.58), so it has no meaningful P/E ratio.
How much revenue does Zeo ScientifiX make?
Zeo ScientifiX reported revenue of $6.99M for the twelve months to Apr 30, 2026.
Does Zeo ScientifiX pay a dividend?
No. Zeo ScientifiX has not paid a cash dividend over the last twelve months.
How has ZEOX stock performed over the past year?
Including dividends, ZEOX returned -54.4% over the past year, against +16.6% for the S&P 500.
Who are Zeo ScientifiX's competitors?
Companies most similar to Zeo ScientifiX by business, industry and size include ELOX, DYAI, LCTX, ELUT, SRZN.
See a number that looks wrong?